Fingerprint
Dive into the research topics of 'Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
Francesco D'Amore, John Radford, Thomas Relander, Mats Jerkeman, Hervé Tilly, Anders Österborg, Franck Morschhauser, Martin Gramatzki, Martin Dreyling, Bo Bang, Hans Hagberg
Research output: Contribution to journal › Article › peer-review